UNSPSC 51352410: Ethinyl estradiol/etonogestrel

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352410 Ethinyl estradiol/etonogestrel is a Commodity code covering this specific hormonal contraceptive formulation, which state and local governments procure primarily through pharmacy benefit programs and cooperative purchasing vehicles for distribution to employees, retirees, and eligible beneficiaries. Recent solicitations show health agencies sourcing this product as part of broader generic pharmaceutical portfolios rather than as a standalone line item. Issuing bodies include state health and human services departments and multistate cooperative purchasing alliances. The Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) both actively solicit pharmaceutical products including generic contraceptives under their respective programs, signaling sustained procurement interest among state-level pharmacy benefit and employee health coverage programs.

Geographic activity centers on Texas and Minnesota, with MMCAP's reach extending to participating states including Oregon. The Texas HHS Commission issued a Request for Information (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct contracts between state pharmacy benefit programs and manufacturers to improve fulfillment efficiency and cost management; this exploratory RFI precedes a formal RFP and does not commit to specific funding or timelines. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) with a March 26, 2026, response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, requiring vendors to supply through three authorized wholesalers with product availability by May 15, 2026, and contract effectiveness July 1, 2026. Pricing is weighted at 75 percent of the evaluation, with competitive formats including flat pricing, net price structures, or WAC-minus models. Both solicitations reflect state procurement interest in managing pharmaceutical costs and ensuring reliable supply chains for employee and beneficiary populations.